1. Smoking and COVID-19 outcomes: an observational and Mendelian randomisation study using the UK Biobank cohort.
- Author
-
Clift AK, von Ende A, Tan PS, Sallis HM, Lindson N, Coupland CAC, Munafò MR, Aveyard P, Hippisley-Cox J, and Hopewell JC
- Subjects
- Biological Specimen Banks, COVID-19 Testing, England, Humans, SARS-CoV-2, Smoking adverse effects, COVID-19
- Abstract
Background: Conflicting evidence has emerged regarding the relevance of smoking on risk of COVID-19 and its severity., Methods: We undertook large-scale observational and Mendelian randomisation (MR) analyses using UK Biobank. Most recent smoking status was determined from primary care records (70.8%) and UK Biobank questionnaire data (29.2%). COVID-19 outcomes were derived from Public Health England SARS-CoV-2 testing data, hospital admissions data, and death certificates (until 18 August 2020). Logistic regression was used to estimate associations between smoking status and confirmed SARS-CoV-2 infection, COVID-19-related hospitalisation, and COVID-19-related death. Inverse variance-weighted MR analyses using established genetic instruments for smoking initiation and smoking heaviness were undertaken (reported per SD increase)., Results: There were 421 469 eligible participants, 1649 confirmed infections, 968 COVID-19-related hospitalisations and 444 COVID-19-related deaths. Compared with never-smokers, current smokers had higher risks of hospitalisation (OR 1.80, 95% CI 1.26 to 2.29) and mortality (smoking 1-9/day: OR 2.14, 95% CI 0.87 to 5.24; 10-19/day: OR 5.91, 95% CI 3.66 to 9.54; 20+/day: OR 6.11, 95% CI 3.59 to 10.42). In MR analyses of 281 105 White British participants, genetically predicted propensity to initiate smoking was associated with higher risks of infection (OR 1.45, 95% CI 1.10 to 1.91) and hospitalisation (OR 1.60, 95% CI 1.13 to 2.27). Genetically predicted higher number of cigarettes smoked per day was associated with higher risks of all outcomes (infection OR 2.51, 95% CI 1.20 to 5.24; hospitalisation OR 5.08, 95% CI 2.04 to 12.66; and death OR 10.02, 95% CI 2.53 to 39.72)., Interpretation: Congruent results from two analytical approaches support a causal effect of smoking on risk of severe COVID-19., Competing Interests: Competing interests: PST reports personal fees from AstraZeneca, and personal fees from Duke-NUS, outside the submitted work. CACC reports receiving personal fees from ClinRisk, outside this work. MRM reports grants from Pfizer and Rusan, outside the submitted work. JHC is an unpaid director of QResearch, a not-for-profit organisation which is a partnership between the University of Oxford and EMIS Health. JHC is a founder and shareholder of ClinRisk Ltd and was its medical director until 31 May 2019; ClinRisk produces open and closed source software to implement clinical risk algorithms (outside this work) into clinical computer systems. AvE and JCH work at the Clinical Trial Service Unit and Epidemiological Studies Unit, which receives research grants from industry that are governed by University of Oxford contracts that protect its independence, and has a staff policy of not taking personal payments from industry; further details can be found at https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf. AKC, HMS, NL and PA have no conflicts to disclose., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF